Figures & data
Table 1. Classification of the reviewed companies in groups.
Figure 1. Outcomes of drugs submitted to EMA for OMP designation in the last 6 years (data for 2016 incomplete).
Figure 2. Technologies supporting newly proposes rare disease treatments.
Table 2. Comparative economic results according to two different segmentations.